Eaton Vance Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Eaton Vance Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,439	Closed	-$44K	–	1868
2021 Q4	$44K	Sell	5,439 -6,394	-54%	-$58.4K	﹤0.01%	2149
2021 Q3	$116K	Sell	11,833 -20,302	-63%	-$160K	﹤0.01%	1413
2021 Q2	$216K	Hold	32,135	–	–	﹤0.01%	1572
2021 Q1	$291K	Hold	32,135	–	–	﹤0.01%	1390
2020 Q4	$215K	Hold	32,135	–	–	﹤0.01%	1402
2020 Q3	$162K	Hold	32,135	–	–	﹤0.01%	1306
2020 Q2	$260K	Hold	32,135	–	–	﹤0.01%	1216
2020 Q1	$255K	Hold	32,135	–	–	﹤0.01%	1178
2019 Q4	$243K	Hold	32,135	–	–	﹤0.01%	1254
2019 Q3	$134K	Sell	32,135 -2,565	-7%	-$6.42K	﹤0.01%	1272
2019 Q2	$100K	Hold	34,700	–	–	﹤0.01%	1281
2019 Q1	$50K	Hold	34,700	–	–	﹤0.01%	1230
2018 Q4	$90K	Hold	34,700	–	–	﹤0.01%	1160
2018 Q3	$152K	Hold	34,700	–	–	﹤0.01%	1183
2018 Q2	$213K	Hold	34,700	–	–	﹤0.01%	1147
2018 Q1	$253K	Hold	34,700	–	–	﹤0.01%	1065
2017 Q4	$285K	Hold	34,700	–	–	﹤0.01%	1059
2017 Q3	$364K	Hold	34,700	–	–	﹤0.01%	997
2017 Q2	$383K	Hold	34,700	–	–	﹤0.01%	979
2017 Q1	$336K	Buy	+34,700	New	+$347K	﹤0.01%	958
2016 Q4	–	Sell	-34,700	Closed	-$430K	–	1004
2016 Q3	$430K	Hold	34,700	–	–	﹤0.01%	865
2016 Q2	$373K	Hold	34,700	–	–	﹤0.01%	862
2016 Q1	$383K	Hold	34,700	–	–	﹤0.01%	830
2015 Q4	$424K	Hold	34,700	–	–	﹤0.01%	830
2015 Q3	$566K	Hold	34,700	–	–	﹤0.01%	768
2015 Q2	$735K	Hold	34,700	–	–	﹤0.01%	684
2015 Q1	$624K	Hold	34,700	–	–	﹤0.01%	763
2014 Q4	$594K	Hold	34,700	–	–	﹤0.01%	746
2014 Q3	$497K	Hold	34,700	–	–	﹤0.01%	755
2014 Q2	$521K	Hold	34,700	–	–	﹤0.01%	749
2014 Q1	$464K	Hold	34,700	–	–	﹤0.01%	753
2013 Q4	$279K	Hold	34,700	–	–	﹤0.01%	804
2013 Q3	$228K	Hold	34,700	–	–	﹤0.01%	790
2013 Q2	$213K	Buy	+34,700	New	+$179K	﹤0.01%	801

Other funds holding AVDL

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Eaton Vance Management's AVDL Position: Q1 2022 in Review

Eaton Vance Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2022, closing a stake of 5,439 shares — an estimated $44K sold.

Eaton Vance Management first reported a position in AVDL in Q2 2013 and held it in 34 quarters. The position peaked at $735K in Q2 2015. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2022.

Eaton Vance Management reported no remaining Avadel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 5,439 Avadel Pharmaceuticals shares in Q1 2022, an estimated $44K.
Eaton Vance Management first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 34 quarters.
Eaton Vance Management's Avadel Pharmaceuticals position peaked at $735K in Q2 2015.
81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.